Femur

Michael Greller, MD, FAAOS, and Garret Sobol, MD, of AOSMI Are the First in Monmouth County, NJ to Perform Innovative BEAR® Implant to Treat ACL Tears

Retrieved on: 
Friday, February 17, 2023
MBA, Patient satisfaction, ACL, Motion, Fellow, Blood, Knee pain, Patient, MRI, Anterior cruciate ligament, Orthopedic surgery, CPE, Suture, Leg, Podiatry, Tibia, American Sports Medicine Institute, Risk, Femur, Facial muscles, Knee, Infection, Multimedia, Elective surgery, BEAR, Rupture, Medial knee injuries, MD, Dentistry, Medical device, Sports medicine

FREEHOLD, N.J., Feb. 17, 2023 /PRNewswire/ -- Advanced Orthopedics and Sports Medicine Institute (AOSMI) is the first in Monmouth County, NJ to perform the BEAR® (Bridge-Enhanced ACL Repair/Restoration) Implant for treatment of anterior cruciate ligament (ACL) tears, one of the most common knee injuries in the U.S. The BEAR Implant is the first medical advancement to enable the body to heal its own torn ACL. This innovative approach is a change in basic assumptions from the current standard of care – reconstruction that replaces the ACL with a graft – and is the first innovation in ACL tear treatment in more than 30 years.

Key Points: 
  • The BEAR Implant is the first medical advancement to enable the body to heal its own torn ACL.
  • Michael J. Greller, MD, MBA, CPE, FAAOS, a Board-Certified Orthopedic Surgeon who is Fellowship-trained in Sports Medicine led the procedure.
  • The BEAR Implant, positioned on sutures, acts as a bridge to help ends of the torn ACL heal together.
  • The BEAR Implant has the same potential medical and surgical complications as other orthopedic surgical procedures, including ACL reconstruction.

2023 Kappa Delta Ann Doner Vaughn Award Presented to Michelle Ghert, MD, FRCSC, and the PARITY Investigators for First-Ever International Multi-Center Randomized Controlled Trial in Orthopaedic Oncology

Retrieved on: 
Friday, February 10, 2023
Cefuroxime, Clostridioides, Caregiver, Christianity in Singapore, McMaster University, Journal, Infection, Bone, Pelvic floor dysfunction, American Medical Association, Korea Disease Control and Prevention Agency, The Journal of Bone and Joint Surgery, Antibiotic prophylaxis, Antibiotic-associated diarrhea, Clostridioides difficile, Medicine, Patient, Cancer, Cefazolin, Megacolon, Staphylococcus, Oncology, Kappa Delta, Biostatistics, Incidence, Database, Bone sarcoma, Research, RCT, Soft-tissue sarcoma, Tibia, Mortality, Amputation, Risk, FRCSC, CDC, Optimism, Staphylococcus aureus, Immune system, Femur, Survival, MD, SSI, Quality of life, Surgeon, Bone disease, Doctor of Philosophy, JAMA Oncology, Dentistry, Pharmaceutical industry

Their work resulted in the first-ever international, multi-center randomized controlled trial (RCT) in orthopaedic oncology as well as the largest collaborative effort in orthopaedic surgery with regards to the number of countries collaborating.

Key Points: 
  • Their work resulted in the first-ever international, multi-center randomized controlled trial (RCT) in orthopaedic oncology as well as the largest collaborative effort in orthopaedic surgery with regards to the number of countries collaborating.
  • "However, in orthopaedic oncology, where we treat rare diseases, it was a shift in our research paradigm.
  • I give a lot of credit to the first few clinical sites that joined the study as they took a leap of faith."
  • The PARITY investigators work resulted in 13 manuscripts published in peer-reviewed journals, including The Journal of the American Medical Association (Oncology).

FDA Provides Clearance of First-Ever Device for ACL Reconstruction in Children

Retrieved on: 
Tuesday, January 10, 2023
Hospital for Special Surgery, Eugene R. Black Sr., Meta-analysis, Child, ACL, Hope, Anterior cruciate ligament reconstruction, Arthroscopy (journal), Summative assessment, Growth, DRS, HSS, Team, Patient, Anterior cruciate ligament, Education, Regulation of tobacco by the U.S. Food and Drug Administration, Adolescence, Research, Knee, Instability, PMID, Sports medicine, Physician, FDA, Femur, Tears, Food, EPUB, Sport, Surgeon, Tibia, Systematic review, Delos D. Harriman, Medial knee injuries, Seven Second Surgery, Francesco Cordasco, Ligament, FACS, MM, Risk, Pediatrics, Price M. Cobbs, Fabricant, Hospital, Autotransplantation, Medical imaging, Dentistry, Incidence, MD, Athlete, FAAP, Green

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has provided clearance for use of the ACL TightRope® II implant as the first-ever device for reconstructing torn knee ligaments in children and adolescents. The technology is based on a related device commonly used in adults undergoing anterior cruciate ligament (ACL) reconstruction, but with features specifically designed to accommodate the growing skeletons of young athletes. The key advantage of the new technique is that it allows surgeons to tension the graft sequentially to ensure proper fixation and strength and to utilize minimally invasive techniques to diminish damage to the growth plates while performing a successful reconstruction.

Key Points: 
  • The technology is based on a related device commonly used in adults undergoing anterior cruciate ligament (ACL) reconstruction, but with features specifically designed to accommodate the growing skeletons of young athletes.
  • Cordasco and Green also developed pediatric- and young-adolescent-specific instrumentation guides to address an increasing population of injured high-risk young athletes.
  • Until relatively recently, however, surgeons were reluctant to operate on children whose growth plates in the legs had not fused.
  • MRI Signal Intensity of Quadriceps Tendon Autograft and Hamstring Tendon Autograft 1 Year After Anterior Cruciate Ligament Reconstruction in Adolescent Athletes.

Conformis Announces First Procedure Performed Using New Actera™ Hip System

Retrieved on: 
Tuesday, November 29, 2022
Software, Growth, Arthralgia, Health, Patient, Joint, Database, Marketing, MD, Patent, Security (finance), Titanium, Surgeon, Risk, Dipterocarpus conformis, Knee, Femur, Medical device, Dentistry, Actera Group

BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure with the companys new ActeraHip System has been performed.

Key Points: 
  • BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure with the companys new ActeraHip System has been performed.
  • Dr. William Kurtz, MD performed the hip replacement procedure at Ascension Saint Thomas Hospital in Nashville, Tennessee, using a minimally invasive direct-anterior approach.
  • The Actera hip system is a great new option for hip reconstruction surgeons, said Dr. Kurtz.
  • In addition, the hip system has two head-center options in each size, enabling a more intuitive intraoperative experience.

Man Crushed by Boulder on Hike Returns to Raise Money for Families and Victims of Human Trafficking

Retrieved on: 
Monday, November 21, 2022
Arizona Trail, Housing, Prayer, Life, Survivor, Annalee, Ryukyu Kingdom, Netflix, Violence, Short Creek Community, Dream Center, Poverty, Femur, General store, Drug

Luke and Annalee were 500 miles into the hike when an 8,000-pound boulder came bombing down toward Annalee.

Key Points: 
  • Luke and Annalee were 500 miles into the hike when an 8,000-pound boulder came bombing down toward Annalee.
  • Heroically, Luke pushed his daughter out of the way, saving her, and, in turn, was crushed and dragged by the boulder himself.
  • This story broke internationally and allowed the hikers to raise over $1.8 million in support of the Short Creek Dream Center and Short Creek community.
  • To learn more about the hike and how it's supporting victims and families in the community, visit: https://www.shortcreekdreamcenter.org/adventure-your-life-2-0/ .

Announcement of the Effect of Ginseng and Red Ginseng for Suppression of Bone and Muscle Loss - Announced at the 13th International Symposium on Ginseng 2022

Retrieved on: 
Tuesday, November 8, 2022
Lotte Hotel Moscow, Liver, Ageing, Muscle, Spine, Professor, Infection, COVID 19, Bone loss, Ministry, Sarcopenia, Lotte Hotels & Resorts, Time-invariant system, Soonchunhyang University, University, COVID, Water, Fatigue, Immunity, Femur, Chungnam National University, Mouse, Research, RD, Male, Adult, Dietary supplement, Food

SEOUL, South Korea, Nov. 8, 2022 /PRNewswire/ -- The Korean Ginseng Society held the 13th International Ginseng Symposium from October 25 to 28 at the Lotte Hotel in Seoul.

Key Points: 
  • SEOUL, South Korea, Nov. 8, 2022 /PRNewswire/ -- The Korean Ginseng Society held the 13th International Ginseng Symposium from October 25 to 28 at the Lotte Hotel in Seoul.
  • Korean ginseng (Panax ginseng) has been used for various treatments for about 2,000 years, and is the most used in Dongui Bogam, a traditional Korean medical book.
  • Professor Hyuk-Young Kwon's team at Soonchunhyang University announced the inhibitory effect of ginsenoside Rd on sarcopenia.
  • In addition, significant bone loss occurred in the femur and spine of mice after antibiotic treatment, but bone loss was prevented in the group treated with red ginseng.

RSIP Vision Presents Successful Preliminary Results from Clinical Study of 2D-to-3D Knee Bones Reconstruction

Retrieved on: 
Thursday, October 27, 2022
Knee, SAN, Femur, Osteochondrodysplasia, Anatomical terms of location, Acquisition, AI, RSIP, Medical device, TEL, Industry, CA, Technology, FDA, Assuta Medical Center, Population, 3D, Tibia, TKA, Anatomy, Trial of the century, Software, Multimedia, Hip, AP, Safran, Radiation, Medical imaging

TEL AVIV, Israel and SAN JOSE, Calif., Oct. 27, 2022 /PRNewswire/ -- RSIP Vision, an experienced developer of  groundbreaking AI technologies for medical imaging, today reveals preliminary results from an ongoing clinical study for the evaluation of the reconstruction of a 3D knee model from 2D X-ray images at Assuta Medical Center in Tel Aviv. This tool is based on novel, patent-pending technology, implementing advanced artificial intelligence (AI) to produce an accurate model of the knee from two X-ray images of the knee (Anteroposterior and lateral views). This model can be used for surgical planning and navigation during knee orthopedic procedures, such as total knee replacement.

Key Points: 
  • "Robotic and patient-specific solutions for total knee arthroplasty (TKA) often require a CT scan for accurate 3D reconstruction of the knee bones."
  • "Our knee reconstruction solution utilizes two standard X-ray images to produce a 3D model of the knee joint, comparable to the CT-based models.
  • Our preliminary clinical study results demonstrate high accuracy, which we expect will be suitable for clinical applications.
  • RSIP Vision plans to expand this clinical study into a medical center in the USA, and ultimately receive FDA clearance.

JAG-ONE Physical Therapy Moves Forward as First Multi-Site Northeast Company to Offer Certified Post Operative Rehabilitation to Treat Innovative BEAR® Implant For ACL Tears

Retrieved on: 
Monday, October 17, 2022
Leg, Elective surgery, Risk, Diagnosis, Tibia, Infection, Medial knee injuries, ACL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Twitter, Instagram, New Jersey Devils, Anterior cruciate ligament, Jersey Devil, MRI, Rupture, BEAR, De novo, Food, Sport, Femur, Motion, Blood, Knee pain, CEO, Pain, Columbia Lions, Injury, Occupational therapy, Surgeon, Dentistry, Medical device, Facebook

BRIDGEWATER, N.J., Oct. 17, 2022 /PRNewswire/ -- JAG-ONE Physical Therapy, one of the fastest-growing comprehensive physical and occupational therapy practices in the Northeast, announces today that they are the first in the region to rehabilitate the innovative BEAR® Implant reconstruction surgery of anterior cruciate ligament (ACL) tears, one of the most common knee injuries in the U.S. The BEAR Implant is the first medical advancement to enable the body to heal its torn ACL. This new approach is a shift from the current standard of care – reconstruction that replaces the ACL with a graft and is the first innovation in ACL tear treatment in more than 30 years.

Key Points: 
  • The BEAR Implant is the first medical advancement to enable the body to heal its torn ACL.
  • Yearly, approximately 400,000 ACL injuries occur in the U.S. Torn ACL does not heal without treatment, making ACL reconstruction one of the most common orthopedic procedures in the U.S.
  • JAG-ONE Physical Therapy is the official provider of physical therapy for sports teams such as the New Jersey Devils, Columbia University Athletics, and Princeton University Athletics.
  • For more information on JAG-ONE Physical Therapy, visit jagonept.com and find JAG-ONE on Twitter, Facebook , and Instagram .

Miach Orthopaedics Appoints Arjun Ishwar Vice President of Sales & Marketing

Retrieved on: 
Tuesday, October 11, 2022
Health, Surgery, Physical Therapy, Medical Devices, Adoption, LinkedIn, Biomedical engineering, National Football League Players Association, Leg, Use, Purdue University, Hospital, Bridge, Tibia, Anatomy, National, ACL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tears, Patient, Research, Twitter, Instagram, Regeneration, Anterior cruciate ligament, NFL, Implant, MRI, Rupture, Technology, BEAR, De novo, Food, Knee, Boston, Marketing, Femur, Merck KGaA v. Integra Lifesciences I, Ltd., Tissue engineering, Blood, Association, CEO, Trauma, Orthopedic surgery, ACell, Regenerative medicine, Bachelor, Ishvara, Leadership, Dentistry, Medical device, Science, Facebook, Miach

Miach Orthopaedics , Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR) Implant, today announced Arjun Ishwar has joined the company as vice president of sales and marketing.

Key Points: 
  • Miach Orthopaedics , Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR) Implant, today announced Arjun Ishwar has joined the company as vice president of sales and marketing.
  • Ishwar brings extensive experience in corporate strategic planning and execution, sales and marketing leadership, and commercialization combined with a technical background in tissue engineering and regenerative medicine.
  • Lending his expertise to the BEAR Implant is a natural fit, said Patrick McBrayer, president and CEO, Miach Orthopaedics.
  • For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Facebook , Instagram , Twitter and LinkedIn .

Conformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, September 13, 2022
Software, Knee, Risk, Muscle, FDA, Food, Health, Chronology, Growth, U.S. Securities and Exchange Commission, Â, Regulation of tobacco by the U.S. Food and Drug Administration, Elective surgery, Solution, CT, Arthralgia, Thigh, Private Securities Litigation Reform Act, Clinical professor, Dipterocarpus conformis, NASDAQ, Board, Femur, Security (finance), Mayo Clinic, GLOBE, Patent, Joint, THA, Anatomy, Medical device, Actera Group

Conformis will introduce the Actera hip system under a limited market release in select U.S. markets, which is expected to commence in the coming months.

Key Points: 
  • Conformis will introduce the Actera hip system under a limited market release in select U.S. markets, which is expected to commence in the coming months.
  • Chronology of the Conformis Hip Portfolio:
    Conformis Actera Hip System: The Conformis Actera Hip System received FDA 510(k) marketing clearance in 2022.
  • Conformis Cordera Hip System: The Conformis CorderaHip System received FDA 510(k) marketing clearance in 2020.
  • Conformis Hip System: The Conformis Hip System received FDA 510(k) marketing clearance in 2019.